Literature DB >> 16818371

Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.

Heather L Wilson1, Arshud Dar, Scott K Napper, A Marianela Lopez, Lorne A Babiuk, George K Mutwiri.   

Abstract

Unmethylated CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides activate immune cells that express Toll-like Receptor 9. Activation through this receptor triggers cellular signaling that leads to production of a proinflammatory and a Th1-type, antigen-specific immune response. The immunostimulatory effects of CpG oligodeoxynucleotides confer protection against infectious disease, allergy and cancer in animal models, and clinical trials have been initiated. However, CpG oligodeoxynucleotides may exacerbate disease in some situations. We will review current concepts in the mechanisms of activating Toll-like Receptor 9 with CpG oligodeoxynucleotides and highlight opportunities for using large animal models to better determine the mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818371     DOI: 10.1080/08830180600785868

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  17 in total

Review 1.  Immune modulatory oligonucleotides in the prevention and treatment of allergen-induced eustachian tube dysfunction in the animal model.

Authors:  Deidra A Blanks; Charles S Ebert
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

2.  Altered lymphocyte proliferation and innate immune function in scrapie 139A- and ME7-infected mice.

Authors:  In Soo Cho; Daryl S Spinner; Richard J Kascsak; H Cliff Meeker; Bo Sook Kim; Seung Yong Park; Georgia Schuller-Levis; Eunkyue Park
Journal:  Viral Immunol       Date:  2013-05-08       Impact factor: 2.257

3.  Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.

Authors:  Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

Review 4.  [Adjuvants].

Authors:  R Brehler
Journal:  Hautarzt       Date:  2017-04       Impact factor: 0.751

Review 5.  Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses.

Authors:  Glen N Barber
Journal:  Curr Opin Immunol       Date:  2011-01-14       Impact factor: 7.486

6.  Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections.

Authors:  Elina I Zuniga; Li-Ying Liou; Lauren Mack; Marilyn Mendoza; Michael B A Oldstone
Journal:  Cell Host Microbe       Date:  2008-10-16       Impact factor: 21.023

7.  Murine J774 macrophages recognize LPS/IFN-g, non-CpG DNA or two-CpG DNA-containing sequences as immunologically distinct.

Authors:  Lynn Crosby; Warren Casey; Kevin Morgan; Hong Ni; Lawrence Yoon; Marilyn Easton; Mary Misukonis; Gary Burleson; Dipak K Ghosh
Journal:  Nitric Oxide       Date:  2010-01-25       Impact factor: 4.427

8.  TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection.

Authors:  Patricia A Taylor; Michael J Ehrhardt; Christopher J Lees; Angela Panoskaltsis-Mortari; Arthur M Krieg; Arlene H Sharpe; William J Murphy; Jonathan S Serody; Hiroaki Hemmi; Shizuo Akira; Robert B Levy; Bruce R Blazar
Journal:  Blood       Date:  2008-07-09       Impact factor: 22.113

9.  Immunomodulatory oligonucleotides inhibit neutrophil migration by decreasing the surface expression of interleukin-8 and leukotriene B4 receptors.

Authors:  Charlotte Admyre; Lars-Göran Axelsson; Oliver von Stein; Arezou Zargari
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

Review 10.  Anti-tumour strategies aiming to target tumour-associated macrophages.

Authors:  Xiaoqiang Tang; Chunfen Mo; Yongsheng Wang; Dandan Wei; Hengyi Xiao
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.